Limits...
Antitumor effect of fibrin glue containing temozolomide against malignant glioma.

Anai S, Hide T, Takezaki T, Kuroda J, Shinojima N, Makino K, Nakamura H, Yano S, Kuratsu J - Cancer Sci. (2014)

Bottom Line: Our high-power liquid chromatography studies indicated that FG containing TMZ (TMZ-FG) manifested a sustained drug release potential.In both phases, TMZ-FG failed to severely damage normal brain tissue.TMZ-FG may represent a safe new drug delivery system with sustained drug release potential to treat malignant glioma.

View Article: PubMed Central - PubMed

Affiliation: Department of Neurosurgery, Kumamoto University Graduate School of Medical Science, Honjo, Chuo-ku, Kumamoto, Japan.

Show MeSH

Related in: MedlinePlus

High-performance liquid chromatography (HPLC) of the temozolomide (TMZ) released from fibrin glue (FG). (a) HPLC of the calibration curve standards. (b) HPLC of PBS incubated for 24 h with FG sheets containing TMZ (TMZ-FGS). (c) Time-course of the total amount of TMZ released from FG (n = 3). (d) Ratio of TMZ released from FG in the course of 168 h (n = 3). For analysis we used the unpaired two-tailed t-test. *P < 0.05. **P < 0.001. NS, not significant.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4317836&req=5

fig02: High-performance liquid chromatography (HPLC) of the temozolomide (TMZ) released from fibrin glue (FG). (a) HPLC of the calibration curve standards. (b) HPLC of PBS incubated for 24 h with FG sheets containing TMZ (TMZ-FGS). (c) Time-course of the total amount of TMZ released from FG (n = 3). (d) Ratio of TMZ released from FG in the course of 168 h (n = 3). For analysis we used the unpaired two-tailed t-test. *P < 0.05. **P < 0.001. NS, not significant.

Mentions: We performed HPLC three times per sample to assay the release of TMZ from FGS containing 0.5 mM or 1 mM TMZ. The TMZ peak of the calibration curve standards and samples appeared at approximately 2.19 min (Fig.2a,b). The FGS containing 1 mM TMZ continued to release a greater amount of TMZ over the course of the 168-h observation period (Fig.2c). Up until 48 h the ratio of released TMZ was similar at the two TMZ concentrations; a significant difference was observed after 72 h (Fig.2d). The FGS containing 1 mM TMZ continued to release TMZ gradually over the entire 168-h observation period. This shows that TMZ was released gradually and that FGS containing the higher concentration of TMZ continued to release the drug at a higher concentration and for a longer period.


Antitumor effect of fibrin glue containing temozolomide against malignant glioma.

Anai S, Hide T, Takezaki T, Kuroda J, Shinojima N, Makino K, Nakamura H, Yano S, Kuratsu J - Cancer Sci. (2014)

High-performance liquid chromatography (HPLC) of the temozolomide (TMZ) released from fibrin glue (FG). (a) HPLC of the calibration curve standards. (b) HPLC of PBS incubated for 24 h with FG sheets containing TMZ (TMZ-FGS). (c) Time-course of the total amount of TMZ released from FG (n = 3). (d) Ratio of TMZ released from FG in the course of 168 h (n = 3). For analysis we used the unpaired two-tailed t-test. *P < 0.05. **P < 0.001. NS, not significant.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4317836&req=5

fig02: High-performance liquid chromatography (HPLC) of the temozolomide (TMZ) released from fibrin glue (FG). (a) HPLC of the calibration curve standards. (b) HPLC of PBS incubated for 24 h with FG sheets containing TMZ (TMZ-FGS). (c) Time-course of the total amount of TMZ released from FG (n = 3). (d) Ratio of TMZ released from FG in the course of 168 h (n = 3). For analysis we used the unpaired two-tailed t-test. *P < 0.05. **P < 0.001. NS, not significant.
Mentions: We performed HPLC three times per sample to assay the release of TMZ from FGS containing 0.5 mM or 1 mM TMZ. The TMZ peak of the calibration curve standards and samples appeared at approximately 2.19 min (Fig.2a,b). The FGS containing 1 mM TMZ continued to release a greater amount of TMZ over the course of the 168-h observation period (Fig.2c). Up until 48 h the ratio of released TMZ was similar at the two TMZ concentrations; a significant difference was observed after 72 h (Fig.2d). The FGS containing 1 mM TMZ continued to release TMZ gradually over the entire 168-h observation period. This shows that TMZ was released gradually and that FGS containing the higher concentration of TMZ continued to release the drug at a higher concentration and for a longer period.

Bottom Line: Our high-power liquid chromatography studies indicated that FG containing TMZ (TMZ-FG) manifested a sustained drug release potential.In both phases, TMZ-FG failed to severely damage normal brain tissue.TMZ-FG may represent a safe new drug delivery system with sustained drug release potential to treat malignant glioma.

View Article: PubMed Central - PubMed

Affiliation: Department of Neurosurgery, Kumamoto University Graduate School of Medical Science, Honjo, Chuo-ku, Kumamoto, Japan.

Show MeSH
Related in: MedlinePlus